Pancreatic Neuroendocrine Tumors Are Characterized by Loss of Noxa Expression that
Can be Recovered by the Proteasome Inhibitor Bortezomib
Open Access JCT
33
E. Van Cutsem, T.J. Hobday, T. Okusaka, J. Capdevila, E.
G. E. de Vries, P. Tomassetti, M. E. Pa vel, S. Hoosen, T.
Haas, J. Lincy, D. Lebwohl and K. Öberg, “Everolimus
for Advanced Pancreatic Neuroendocrine Tumors,” The
New England Journal of Medicine, Vol. 364, 2011, pp.
514-523. http://dx.doi.org/10.1056/NEJMoa1009290
[5] G. Klöppel, P. A. Intveld, B. Stamm and P. U. Heitz,
“The Endocrine Pancreas,” In: K. Kovacs and S. L. Asa,
Eds., Functional Endocrine Pathology, Blackwell Scien-
tific Publications, Boston, 1990, pp. 396-421.
[6] T. Shibue, K. Takeda, E. Oda, H. Tanaka, H. Murasawa,
A. Takaoka, Y. Morishita, S. Akira, T. Taniguchi and N.
Tanaka, “Integral Role of Noxa in p53-Mediated Apop-
totic Response,” Genes & Development, Vol. 17, 2003,
pp. 2233-2238. http://dx.doi.org/10.1101/gad.1103603
[7] J.-Z. Qin, J. Ziffra, L. Stennett, B. Bodner, B. K. Bonish,
V. Chaturvedi, F. Bennett, P. M. Pollock, J. M. Trent, M.
J. C. Hendrix, P. Rizzo, L. Miele and B. J. Nickoloff,
“Proteasome Inhibitors Trigger NOXA-Mediated Apop-
tosis in Melanoma and Myeloma Cells,” Cancer Re-
search, Vol. 65, 2005, pp. 6282-6293.
http://dx.doi.org/10.1158/0008-5472.CAN-05-0676
[8] Y. Fernandez, M. Verhaegen, T. P. Miller, J. L. Rush, P.
Steiner, A. W. Opipari, S. W. Lowe and M. S. Soengas,
“Differential Regulation of Noxa in Normal Melanocytes
and Melanoma Cells by Proteasome Inhibition: Thera-
peutic Implications,” Cancer Research, Vol. 65, 2005, pp.
6294-6304.
http://dx.doi.org/10.1158/0008-5472.CAN-05-0686
[9] E. P. Slater, V. Fendrich, J. Waldmann, E. Nalbatow, B.
Chaloupka and D. K. Bartsch, “Down-regulation of the
Noxa Gene in Gastrinomas,” Experimental and Clinical
Endocrinology & Diabetes, 2006.
[10] A. K. Jansson, A. M. Emterling, G. Arbman and X.-F.
Sun, “Noxa in Colorectal Cancer: A Study on DNA,
mRNA and Protein Expression,” Oncogene, Vol. 22,
2003, pp. 4675-4678.
http://dx.doi.org/10.1038/sj.onc.1206655
[11] G. Rindi and G. Klöppel, “Endocrine Tumors of the Gut
and Pancreas Tumor Biology and Classification,” Neuro-
endocrinology, Vol. 80, Suppl. 1, 2004, pp. 12-15.
http://dx.doi.org/10.1159/000080733
[12] E. P. Slater, S. M. Diehl, P. Langer, B. Samans, A.
Ramaswamy, A. Zielke and D. K. Bartsch, “Analysis by
cDNA Microarrays of Gene Expression Patterns of Hu-
man Adrenocortical Tumors,” European Journal of En-
docrinology, Vol. 154, 2006, pp. 587-598.
http://dx.doi.org/10.1530/eje.1.02116
[13] B. M. Evers, J. Ishizuka, C. M. Townsend and J. C.
Thompson, “The Human Carcinoid Cell Line, BON,”
Annals of the New York Academy of Sciences, Vol. 733,
1994, pp. 393-406.
http://dx.doi.org/10.1111/j.1749-6632.1994.tb17289.x
[14] M. A. Nikiforov, M. Riblett, W. H. Tang, V. Gratchouck,
D. Zhuang, Y. Fernandez, M. Verhaegen, S. Varambally,
A. M. Chinnaiyan, A. J. Jakubowiak and M. S. Soengas,
“Tumor Cell-Selective Regulation of NOXA by c-MYC
in Response to Proteasome Inhibition,” Proceedings of
the National Academy of Sciences of the United States,
Vol. 104, No. 9, 2007, pp. 19488-19493.
http://dx.doi.org/10.1073/pnas.0708380104
[15] S. T. Nawrocki, J. S. Carew, K. H. Maclean, J. F. Cour-
age, P. Huang, J. A. Houghton, J. L. Cleveland, F. J.
Giles and D. J. McConkey, “Myc Regulates Aggresome
Formation, the Induction of Noxa, and Apoptosis in Re-
sponse to the Combination of Bortezomib and SAHA,”
Blood, Vol. 112, No. 7, 2008, pp. 2917-2926.
http://dx.doi.org/10.1182/blood-2007-12-130823
[16] J. Voortman, A. Checinska, G. Giaccone, J. A. Rodriguez
and F. A. E. Kruyt, “Bortezomib, but not Cisplatin, In-
duces Mitochondria-Dependent Apoptosis Accompanied
by Up-Regulation of Noxa in the Non-Small Cell Lung
Cancer Cell Line NCI-H460,” Molecular Cancer Thera-
peutics, Vol. 6, No. 3, 2007, pp. 1046-1053.
http://dx.doi.org/10.1158/1535-7163.MCT-06-0577
[17] D. Lindberg, O. Hessman, G. Akerström and G. Westin,
“Cyclin-Dependent Kinase 4 (CDK4) Expression in Pan-
creatic Endocrine Tumors,” Neuroendocrinology, Vol. 86,
2007, pp. 112-118. http://dx.doi.org/10.1159/000106762
[18] I. Arany, P. Rady, B. M. Evers, S. K. Tyring and C. M.
Townsend, “Analysis of Multiple Molecular Changes in
Human Endocrine Tumours,” Surgical Oncology, Vol. 3,
No. 3, 1994, pp. 153-159.
http://dx.doi.org/10.1016/0960-7404(94)90044-2
[19] D. E. Larsson, M. Wickström, S. Hassan, K. Oberg and D.
Granberg, “The Cytotoxic Agents NSC-95397, Brefeldin
A, Bortezomib and Sanguinarine Induce Apoptosis in
Neuroendocrine Tumors in Vitro,” Anticancer Research,
Vol. 30, No. 1, 2010, pp. 149-156.